Brought to you by 
Ophthalmic-focused Alimera goes public, nets $68.4mm
23 Apr 2010
Executive Summary
A year after withdrawing its IPO, which was first filed in July 2008, Alimera Sciences Inc. (back-of-the-eye disorders) has finally gone public. It netted $68.4mm by selling 6.6mm shares at $11, and the company's venture backers bought 1.8mm of that stock. Earlier in April 2010, Alimera had hoped to issue 6mm shares for $15-17.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ophthalmic-focused Alimera goes public, nets $68.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice